Featured Publications (5)
All Selected Publications
Decreasing alloimmunization-specific mortality in sickle cell disease in the United States: Cost-effectiveness of a shared transfusion resource
Ito S, Pandya A, Hauser RG, Krishnamurti L, Stites E, Tormey C, Krumholz HM, Hendrickson JE, Goshua G
American Journal of Hematology
2024
April
FEATURED
RECOGNITIONS:
Recognitions: ASH Oral and ASH Press Program Selection (2 of 2 in 2022)
Practical Impact: Supporting the mission of the 501(c)(3) Alloantibody Exchange www.alloantibody.org
PRACTICAL IMPACT:
Distributional cost-effectiveness of equity-enhancing gene therapy in sickle cell disease in the United States
Goshua G, Calhoun C, Ito S, James L, Luviano A, Krishnamurti L, Pandya A
Annals of Internal Medicine
2023
May
FEATURED
RECOGNITIONS:
Recognitions: ASH Oral and ASH Press Program Selection (1 of 2 in 2022)
Practical Impact: For treatment funding decisions, even if gene therapy is cost-ineffective by conventional CEA standards, it is an equitable therapy per DCEA standards in the United States for patients with sickle cell disease.
PRACTICAL IMPACT:
.png)
Cost-effectiveness of second-line therapies in adults with chronic immune thrombocytopenia
Goshua G, Sinha P, Kunst N, Pischel L, Lee AI, Cuker A
American Journal of Hematology
2023
January
FEATURED
RECOGNITIONS:
Recognitions: ASH Oral, ASH Abstract Achievement Award (2021 ASH Trainee Recipient: Dr. Goshua), Best of ASH for North America, Best of ASH (HTRS), 2022 American Journal of Hematology Young Investigator Award Paper of the Year [Finalist]
Practical Impact: Fills gap in the 2019 ASH ITP Guidelines and shows that the theoretical concerns about splenectomy tripartite risks that led to its decreased utilization in the United States across 2000-2020 do not outweigh treatment benefit. In addition, for patients whose values and preferences align with surgery, splenectomy-early strategies are the cost-effective strategies.
PRACTICAL IMPACT:
.png)
Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura
Goshua G, Sinha P, Hendrickon JE, Tormey C, Bendapudi PK, Lee AI
Blood
2021
February
FEATURED
RECOGNITIONS:
Recognitions: ASH Oral, Best of ASH (HTRS), ASH Abstract Achievement Award (2020 ASH Trainee Recipient: Dr. Goshua). #1 global trend manuscript (PubMed December 2020)
Practical Impact: First health economic evidence of robust caplacizumab cost-ineffectiveness in best-case base-case (even-if analysis) with subsequent 2022 international debates at ISTH (London) and ASH (New Orleans; Education Spotlight)
PRACTICAL IMPACT:
.png)
Cost savings to hospital of rituximab use in severe autoimmune acquired thrombotic thrombocytopenic purpura
Goshua G, Gokhale A, Hendrickson JE, Tormey C, Lee AI
Blood Advances
2020
February
FEATURED
.png)
